Managing Rhino-cerebral Mucormycosis: Institutional Experience

Main Article Content

Kalpesh Patel
Abhishek Gugliani
Dhwani Mehta

Abstract

Introduction


Rhinocerebral mucormycosis is a rapidly progressive life threatening opportunistic fungal disease and usually occurs in individuals with weakened immune system. It is caused by filamentous fungi of Mucorales from class Mucormycotina. After nasal inoculation, it usually spreads to orbit and brain. The common presenting complaints are purulent sinusitis, facial swelling, headache, complaints of vision or palatal ulceration. Despite the many recent advances in the diagnosis and management of mucormycosis, it still carries a high mortality rate.


 


Materials and methods


Here we present our experience in managing 30 such cases of mucormycosis that presented to our department between June 2016 to June 2018.


 


Results


All these patients were started on systemic antifungals with or without surgical debridement. The patients were followed up with repeated nasal endoscopies and imaging studies.


 


Conclusion


Successful treatment of mucormycosis consists of aggressive repeated surgical debridement of necrotic tissue, systemic antifungal therapy and immediate control of underlying systemic diseases. Since there are no clear-cut guidelines, the treatment needs to be individualized on a case to case basis.

Article Details

How to Cite
1.
Patel K, Gugliani A, Mehta D. Managing Rhino-cerebral Mucormycosis: Institutional Experience. BJOHNS [Internet]. 2019Dec.29 [cited 2024May21];27(3):240-2. Available from: https://bjohns.in/journal3/index.php/bjohns/article/view/15
Section
Our experience
Author Biographies

Kalpesh Patel, B.J Medical College, Ahmedabad

Associate Professor, Department of ENT, B.J Medical College, Ahmedabad

Abhishek Gugliani, B.J Medical College, Ahmedabad

Resident, Department of ENT, B.J Medical College, Ahmedabad

Dhwani Mehta, B.J Medical College, Ahmedabad

Resident, Department of ENT, B.J Medical College, Ahmedabad

References

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2002; 13: 236-301

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005; 41:634-53

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13:236-301

Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatment. Current Opin Infect Dis. 2004; 17:517-25

Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of Mucormycosis. Journal of Fungi 2018; 4(3):90

Tissot F, Agrawal S, Pagano L, Petrikkos G et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopooietic stem cell transplant patients. Haematologica 2017; 102:433-44

Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014; 20:5-26

Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: Results of medical and surgical therapy. Ann Thorac Surg. 1994; 57:1044-50.